Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    Tenable® Holdings, Inc. (NASDAQ: TENB), the exposure management company, today announced general availability of Tenable One AI Exposure. With this release, the Tenable One Exposure Management Platform unifies AI protection, discovery and usage governance across the enterprise – including SaaS platforms, cloud services, APIs and agents. AI is deeply embedded and interconnected throughout organizations, creating […] The post Tenable Extends Exposure Management to AI Attack Surface appeared first on Web-Release.